{"id":745211,"date":"2015-04-23T02:30:00","date_gmt":"2015-04-23T02:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/"},"modified":"2025-11-07T01:25:13","modified_gmt":"2025-11-07T06:25:13","slug":"merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/","title":{"rendered":"Merck Announces Results from Phase 2\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\/Elbasvir in Patients with Advanced Chronic Kidney Disease"},"content":{"rendered":"<p class=\"bwalignc\">       C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free        Hepatitis C Treatment Regimen in Treatment-Na\u00efve and        Treatment-Experienced Patients with Advanced Chronic Kidney Disease        Infected with Hepatitis C Virus Genotype 1     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first presentation of data from <i>C-SURFER<\/i>, the<br \/>\n      company\u2019s Phase 2\/3 clinical trial evaluating the investigational<br \/>\n      once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg)<br \/>\n      in patients with advanced chronic kidney disease (CKD) infected with<br \/>\n      chronic hepatitis C virus (HCV) genotype 1 (GT1).<sup>1<\/sup><br \/>\n      Treatment-na\u00efve patients and patients who failed prior pegylated<br \/>\n      interferon HCV therapy, with or without cirrhosis, all of whom had CKD<br \/>\n      stages 4 or 5, were enrolled.<sup>2<\/sup> Following 12 weeks of<br \/>\n      treatment with grazoprevir and elbasvir, 99 percent (115\/116) of<br \/>\n      patients in the pre-specified primary population for analysis of<br \/>\n      efficacy data achieved a sustained virologic response 12 weeks after the<br \/>\n      completion of treatment (SVR12).<sup>3<\/sup> These data will be<br \/>\n      presented today at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Filc-congress.eu%2F&amp;esheet=51085574&amp;newsitemid=20150423005068&amp;lan=en-US&amp;anchor=The+International+Liver+CongressTM+2015&amp;index=1&amp;md5=2970199627f944945a9ef8756bdf26d8\" rel=\"nofollow\">The<br \/>\n      International Liver Congress<sup>TM <\/sup>2015<\/a> \u2013 the 50<sup>th<\/sup><br \/>\n      annual congress of the European Association for the Study of the Liver<br \/>\n      (late breaking E-Poster #LP02).\n    <\/p>\n<p>\n      \u201cThere is an unmet medical need to treat chronic hepatitis C virus<br \/>\n      infection in patients with advanced chronic kidney disease,\u201d said Dr.<br \/>\n      Howard Monsour, Jr., chief of hepatology, Houston Methodist Hospital,<br \/>\n      Houston, Texas. \u201cIn this trial, the first to investigate an all-oral<br \/>\n      ribavirin-free treatment regimen in treatment-na\u00efve and<br \/>\n      treatment-experienced CKD patients, treatment with grazoprevir and<br \/>\n      elbasvir for 12 weeks was effective in this study population with HCV<br \/>\n      genotype 1 infection.\u201d\n    <\/p>\n<p>\n      The ongoing <i>C-SURFER<\/i> Phase 2\/3 clinical trial is a randomized,<br \/>\n      parallel-group, placebo-controlled study evaluating patients infected<br \/>\n      with chronic HCV GT1 with advanced CKD with or without liver cirrhosis.<br \/>\n      Patients were randomized to one of two study arms:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Immediate treatment group (ITG), grazoprevir plus elbasvir (blinded)<br \/>\n        once-daily for 12 weeks (n=111);\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Deferred treatment group (DTG), initially placebo (control arm) for 12<br \/>\n        weeks followed by a four week follow-up period and then treatment with<br \/>\n        grazoprevir plus elbasvir (open label) once-daily for 12 weeks (n=113).\n      <\/li>\n<\/ul>\n<p>\n      In addition, 11 patients received grazoprevir plus elbasvir (open label)<br \/>\n      once-daily for 12 weeks with intensive pharmacokinetic sampling.\n    <\/p>\n<p>\n      Of the 122 patients who received grazoprevir plus elbasvir, 83 percent<br \/>\n      were treatment-na\u00efve, 36 percent had diabetes, 18 percent had stage 4<br \/>\n      CKD, 82 percent had stage 5 CKD, 75 percent were receiving hemodialysis<br \/>\n      and 45 percent were African-American. Among those patients who received<br \/>\n      at least one dose of grazoprevir plus elbasvir, five percent (6\/122)<br \/>\n      were excluded from the pre-specified primary efficacy analysis<br \/>\n      population, or modified full analysis set, due to missing data caused by<br \/>\n      death or early discontinuation for reasons unrelated to study drug. In<br \/>\n      the modified full analysis set, 99 percent (115\/116) of patients<br \/>\n      receiving grazoprevir plus elbasvir achieved SVR12. One GT1b infected,<br \/>\n      non-cirrhotic, interferon-intolerant patient showed a viral relapse at<br \/>\n      follow-up week 12. Within the modified full analysis set, efficacy was<br \/>\n      consistent across the patient sub-populations assessed. In a supportive<br \/>\n      analysis of all 122 patients who received at least one dose of<br \/>\n      grazoprevir plus elbasvir in the ITG arms, including patients who did<br \/>\n      not complete the study for reasons not related to study drug, 94 percent<br \/>\n      (115\/122) of patients achieved SVR12.\n    <\/p>\n<p>\n      \u201cMerck\u2019s broad clinical development program includes studies dedicated<br \/>\n      to bringing a once-daily regimen to diverse populations of patients<br \/>\n      infected with chronic HCV, including certain types of patients with<br \/>\n      co-morbidities, such as advanced chronic kidney disease,\u201d said Dr. Eliav<br \/>\n      Barr, vice president, infectious diseases, Merck Research Laboratories.<br \/>\n      \u201cThese data highlight how emerging innovations in chronic hepatitis C<br \/>\n      treatment may lead to new options for patient populations in which it<br \/>\n      historically has been difficult to achieve high rates of sustained viral<br \/>\n      clearance.\u201d\n    <\/p>\n<p>\n      No patients in the ITG arms discontinued treatment due to adverse events<br \/>\n      (AEs), while four percent (5\/113) of patients in the comparator placebo<br \/>\n      phase of the DTG arm discontinued treatment due to AEs. The rates of<br \/>\n      serious AEs reported were 14 percent (16\/111) in the ITG arms and 17<br \/>\n      percent (19\/113) in the placebo control DTG arm. The most common<br \/>\n      treatment-related AEs in the ITG arms and DTG arm (placebo) were<br \/>\n      headache (17%, 17%), nausea (15%, 16%) and fatigue (10%, 15%),<br \/>\n      respectively. There were four deaths reported during the initial<br \/>\n      treatment phase and the first 14 days of study follow-up. One patient<br \/>\n      (1%) in the open label arm died from cardiac arrest (not considered<br \/>\n      related to study medicine) and three patients (2%) in the placebo group<br \/>\n      died from aortic aneurysm, pneumonia and an unknown cause.\n    <\/p>\n<p>\n      On April 8, 2015, the company announced that the U.S. Food and Drug<br \/>\n      Administration (FDA) had granted Breakthrough Therapy designation to<br \/>\n      grazoprevir\/elbasvir for the treatment of patients infected with chronic<br \/>\n      HCV GT1 with end-stage renal disease on hemodialysis and patients<br \/>\n      infected with chronic HCV GT4. Breakthrough Therapy designation is<br \/>\n      intended to expedite the development and review of a candidate that is<br \/>\n      planned for use, alone or in combination, to treat a serious or<br \/>\n      life-threatening disease or condition when preliminary clinical evidence<br \/>\n      indicates that the drug may demonstrate substantial improvement over<br \/>\n      existing therapies on one or more clinically significant endpoints.\n    <\/p>\n<p>\n      <b>About <i>C-SURFER<\/i><\/b>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02092350&amp;esheet=51085574&amp;newsitemid=20150423005068&amp;lan=en-US&amp;anchor=C-SURFER&amp;index=2&amp;md5=865decb1e26af759585ac4e1da7dba47\" rel=\"nofollow\"><i>C-SURFER<\/i><\/a><br \/>\n      is a Phase 2\/3 clinical trial<i> <\/i>evaluating Merck\u2019s investigational<br \/>\n      grazoprevir plus elbasvir in patients infected with chronic HCV GT1 and<br \/>\n      with advanced chronic kidney disease (stages 4 and 5, including patients<br \/>\n      on hemodialysis) with or without liver cirrhosis, which are among those<br \/>\n      with HCV infection who are most difficult to treat, over 12 weeks.\n    <\/p>\n<p>\n      <b>About Chronic HCV Infection and Chronic Kidney Disease<\/b>\n    <\/p>\n<p>\n      Chronic HCV infection is both a cause and complication of the treatment<br \/>\n      of CKD. In patients with CKD, chronic HCV infection is associated with<br \/>\n      an increased risk of accelerated loss of remaining kidney function,<br \/>\n      kidney transplant failure and death. Furthermore, patients with chronic<br \/>\n      HCV infection and advanced CKD represent an unmet need due to a lack of<br \/>\n      demonstrated HCV treatment options for this group.\n    <\/p>\n<p>\n      <b>About Grazoprevir\/Elbasvir<\/b>\n    <\/p>\n<p>\n      Grazoprevir\/elbasvir is an investigational, once-daily single tablet<br \/>\n      regimen consisting of grazoprevir (NS3\/4A protease inhibitor) and<br \/>\n      elbasvir (NS5A replication complex inhibitor). As part of Merck\u2019s broad<br \/>\n      clinical trials program, grazoprevir\/elbasvir is being studied in<br \/>\n      multiple HCV genotypes and in patients with difficult-to-treat<br \/>\n      conditions such as HIV\/HCV co-infection, advanced chronic kidney<br \/>\n      disease, inherited blood disorders, liver cirrhosis and those on opiate<br \/>\n      substitution therapy.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For nearly 30 years, Merck has been at the forefront of the response to<br \/>\n      the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to deliver innovative<br \/>\n      health care solutions that support people living with HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51085574&amp;newsitemid=20150423005068&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=215e4e99d8c5c3929d0941145c736fbb\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51085574&amp;newsitemid=20150423005068&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=ef22779fb545c670169b5e84dad82939\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51085574&amp;newsitemid=20150423005068&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=5694b80cc1474e179228c33a73db5bca\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51085574&amp;newsitemid=20150423005068&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=9cf0fe51fe35898a0d2d3954f24e2d77\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the U.S. Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of Merck\u2019s management and are subject<br \/>\n      to significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise except as required by applicable law. Additional factors that<br \/>\n      could cause results to differ materially from those described in the<br \/>\n      forward-looking statements can be found in Merck\u2019s 2014 Annual Report on<br \/>\n      Form 10-K and the company\u2019s other filings with the Securities and<br \/>\n      Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51085574&amp;newsitemid=20150423005068&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=776415f4ff9f0e23912bf993b6aaabc6\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> In Phase 2 studies, grazoprevir\/elbasvir are administered<br \/>\n      as two separate tablets\n    <\/p>\n<p>\n      <sup>2<\/sup> Stages 4 and 5 chronic kidney disease are defined as<br \/>\n      severely or very severely reduced kidney function, based on estimated<br \/>\n      glomerular filtration rate &lt;30 mL\/min\/1.73m<sup>2<\/sup>\n    <\/p>\n<p>\n      <sup>3<\/sup> Includes patients who received \u22651 dose of study drug and<br \/>\n      excluded those with missing data because of death or early<br \/>\n      discontinuation for reasons unrelated to study drug\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150423005068r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Media:<br \/>Doris Li, 908-246-5701<br \/>or<br \/>Sarra Herzog,        201-669-6570<br \/>or<br \/>Investors:<br \/>Joe Romanelli, 908-740-1986<br \/>or<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from C-SURFER , the company\u2019s Phase 2\/3 clinical trial evaluating the investigational once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg) in patients with advanced chronic kidney disease (CKD) infected with chronic hepatitis C virus (HCV) genotype 1 (GT1). 1 Treatment-na\u00efve patients and patients who failed prior pegylated interferon HCV therapy, with or without cirrhosis, all of whom had CKD stages 4 or 5, were enrolled. 2 Following 12 weeks of treatment with grazoprevir and elbasvir, 99 percent (115\/116) of patients in the pre-specified primary population for analysis of efficacy data achieved a sustained virologic response 12 weeks after the completion of treatment (SVR12). 3 These data will be presented today at The International Liver CongressTM 2015 \u2013 the 50 th annual congress of the European Association for the Study of the Liver (late breaking<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745211","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Results from Phase 2\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\/Elbasvir in Patients with Advanced Chronic Kidney Disease - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Results from Phase 2\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\/Elbasvir in Patients with Advanced Chronic Kidney Disease - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from C-SURFER , the company\u2019s Phase 2\/3 clinical trial evaluating the investigational once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg) in patients with advanced chronic kidney disease (CKD) infected with chronic hepatitis C virus (HCV) genotype 1 (GT1). 1 Treatment-na\u00efve patients and patients who failed prior pegylated interferon HCV therapy, with or without cirrhosis, all of whom had CKD stages 4 or 5, were enrolled. 2 Following 12 weeks of treatment with grazoprevir and elbasvir, 99 percent (115\/116) of patients in the pre-specified primary population for analysis of efficacy data achieved a sustained virologic response 12 weeks after the completion of treatment (SVR12). 3 These data will be presented today at The International Liver CongressTM 2015 \u2013 the 50 th annual congress of the European Association for the Study of the Liver (late breaking\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\\\/\",\"name\":\"Merck Announces Results from Phase 2\\\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\\\/Elbasvir in Patients with Advanced Chronic Kidney Disease - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-04-23T02:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Results from Phase 2\\\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\\\/Elbasvir in Patients with Advanced Chronic Kidney Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Results from Phase 2\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\/Elbasvir in Patients with Advanced Chronic Kidney Disease - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Results from Phase 2\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\/Elbasvir in Patients with Advanced Chronic Kidney Disease - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from C-SURFER , the company\u2019s Phase 2\/3 clinical trial evaluating the investigational once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg) in patients with advanced chronic kidney disease (CKD) infected with chronic hepatitis C virus (HCV) genotype 1 (GT1). 1 Treatment-na\u00efve patients and patients who failed prior pegylated interferon HCV therapy, with or without cirrhosis, all of whom had CKD stages 4 or 5, were enrolled. 2 Following 12 weeks of treatment with grazoprevir and elbasvir, 99 percent (115\/116) of patients in the pre-specified primary population for analysis of efficacy data achieved a sustained virologic response 12 weeks after the completion of treatment (SVR12). 3 These data will be presented today at The International Liver CongressTM 2015 \u2013 the 50 th annual congress of the European Association for the Study of the Liver (late breaking","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:13+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/","name":"Merck Announces Results from Phase 2\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\/Elbasvir in Patients with Advanced Chronic Kidney Disease - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-04-23T02:30:00+00:00","dateModified":"2025-11-07T06:25:13+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2-3-study-of-investigational-chronic-hepatitis-c-therapy-grazoprevir-elbasvir-in-patients-with-advanced-chronic-kidney-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Results from Phase 2\/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir\/Elbasvir in Patients with Advanced Chronic Kidney Disease"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"97880809-e398-45c7-9ce6-584ffd8ee933","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Results-from-Phase-23-Study-of-Investigational-Chronic-Hepatitis-C-Therapy-GrazoprevirElbasvir-in-Patients-with-Advan-DH0KT.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745211\/revisions"}],"predecessor-version":[{"id":3674650,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745211\/revisions\/3674650"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745211"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}